[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-reported-outcome-pro\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-reported-outcome-pro":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,77,108,138,178,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643615","digital-support-for-multiple-myeloma-quality-of-life-100643615",false,"NCT07642362","Digital Support for Multiple Myeloma Quality of Life","Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)","DigiMyQoL","Inclusion Criteria:\n\n* Adult patients with newly diagnosed or relapsed\u002Frefractory multiple myeloma\n* Patients that are able to use the digital platform\u002Fapplication\n\nExclusion Criteria:\n\n* Patients that are not able to use the digital platform\u002Fapplication","ALL",{"count":19,"type":20},108,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.\n\nSpecifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.",[26,27,28,29],"Multiple Myeloma","Patient Reported Outcome (PRO)","Supportive Care in Cancer","Quality of Life",[31,32,33,34,35,36,37],"multiple myeloma","quality of life","qol","patient reported outcome","pro","digital oncology","supportive care","RECRUITING","2026-06-07",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":42},"2025-02-27",{"date":46,"type":20},"2028-03",{"name":48,"class":49},"CareAcross","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":50},"100631808","screening-for-supportive-care-needs-of-oncological-patients-and-professionals---evaluation-of-a-short-pro-question-set-100631808","NCT07505498","Screening for Supportive Care Needs of Oncological Patients and Professionals - Evaluation of a Short PRO-question Set","Scope-PRO: Screening for Supportive Care Needs of Oncological Patients and Professionals - Evaluation of a Short PRO-question Set","Scope-PRO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Capacity to give consent\n* Cancer patients\n* Sufficient understanding of the German language\n\nExclusion Criteria:\n\n* Minors\n* Lack of capacity to give consent\n* Insufficient knowledge of German","18 Years",{"count":61,"type":20},900,"OBSERVATIONAL","The systematic recording of patient-reported symptoms and health-related quality of life (patient-reported outcomes, PROs) is a central component of oncological care. Currently, however, screening for support needs in German hospitals is inconsistent and uses different assessment tools, leading to heterogeneity, redundant surveys, and limited comparability of results. This complicates standardized, patient-centered, and cross-sector care, as well as the early identification of therapy-associated side effects and support needs.\n\nThe aim of the study is to investigate the acceptance and relevance of the core set of questions from the perspective of both cancer patients and professional healthcare providers. Cancer patient acceptance will be measured by the proportion of fully completed questionnaires, while cancer patient relevance will be assessed using a feedback form. The professional perspective will be gathered through guided feedback in quality circles conducted regularly in accordance with internal standards",[65,66,27],"Patient Related Outcome Measures","Supportive Care","2026-03-29",{"date":69,"type":42},"2026-04-01",{"date":71,"type":42},"2025-12-01",{"date":73,"type":20},"2027-12-31",{"name":75,"class":76},"University Medical Center Goettingen","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":50},"100629062","multidisciplinary-care-pathway-tailored-on-frailty-in-cancer-patients-referred-to-outpatient-palliative-care-100629062","NCT07469761","MultidISciplinary Care paThway tailoRed on frAilty in Cancer Patients Referred to Outpatient paLliative Care","MISTRAL","Inclusion Criteria:\n\n* diagnosis of advanced\u002Fmetastatic cancer\n* age \\> 18\n* Eastern Cooperative Oncology Group (ECOG) performance status ≥2\n* prognostic clinical prediction \\>1 month.\n\nExclusion Criteria:\n\n* Serious medical or psychiatric illness that can interfere with informed consent and participation in this clinical study\n* any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.",{"count":85,"type":20},120,[23],"The goal of this clinical trial is to learn whether a structured, Patient-Reported Outcome Measures (PROMs)-tailored palliative care pathway improves clinical outcomes and care experience in adults with advanced cancer referred to outpatient palliative care.\n\nPatients with advanced cancer often experience multiple symptoms and complex needs. Standard outpatient palliative care is usually guided by clinical judgment on patient-reported questionnaires. In this study, researchers aim to test whether a more structured approach, based on predefined cut-offs from PROMs, can improve symptom control, satisfaction with care, and use of healthcare resources. The main questions the study aims to answer are:\n\nDoes a structured, PROM-driven palliative care pathway reduce symptom burden and psychological distress compared with usual care? And through this, to improve patients' and caregivers' satisfaction with care or reduce emergency room visits, hospital admissions, healthcare costs, and aggressive treatments near the end of life?\n\nResearchers will compare two groups:\n\nControl group: Participants will receive standard outpatient palliative care. PROMs are collected as usual, but without predefined cut-offs or structured intervention checklists.\n\nExperimental group: Participants will receive a structured palliative care pathway tailored to symptoms\u002Fneeds identified at baseline using PROM cut-offs. Specific multidisciplinary interventions are activated according to identified needs.",[89,90,27,91,92,93,94],"Palliative Care","Palliative Care, Health Services","Patient Reported Outcome Measurements","Frailty","Cancer","Outpatient",[96,94,89,97,92,98],"Patient Reported Outcome Measurements (PROMs)","Advanced cancer","Palliative Care intervention","2026-03-09",{"date":101,"type":42},"2026-03-13",{"date":103,"type":42},"2025-11-02",{"date":105,"type":20},"2027-02-28",{"name":107,"class":76},"Augusto Caraceni",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100615167","patient-reported-outcomes-in-allogeneic-stem-cell-transplantation-and-car-t-therapy-100615167","NCT07289087","Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy","A Real-World Observational Study on Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation (Allo-SCT) and CAR-T Therapy","QOL-ONE PRO-CT","Inclusion Criteria:\n\n* Diagnosed with a hematologic malignancy (e.g., leukemia, lymphoma, multiple myeloma)\n* Undergoing either allogeneic SCT or CAR-T therapy\n* Able and willing to provide written informed consent\n* Sufficient Italian proficiency to complete the HM-PRO\n* Signed informed consent\n\nExclusion Criteria:\n\n* Cognitive or physical impairments that preclude the ability to complete questionnaires\n* Estimated life expectancy \\\u003C 7 days at the time of admission",{"count":117,"type":20},162,"3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).",[29,27,120,121],"Allogeneic Blood and Marrow Transplantation (BMT)","CAR T Cell Therapy",[29,123,124,125,126,26,127],"CAR-T cell therapy","Allogenic BMT","Patient Reported Outcome","Leukemia","Lymphoma","NOT_YET_RECRUITING","2025-12-04",{"date":131,"type":42},"2025-12-17",{"date":133,"type":20},"2026-02-15",{"date":135,"type":20},"2027-04-01",{"name":137,"class":76},"Associazione Qol-one",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":160,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":50},"100566450","efficiency-of-the-medidux-smartphone-app-for-demission-management-in-patients-medicated-in-acute-admission-unit-aau-100566450","NCT06655337","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU): a Randomized Controlled Trial.","EffiDux","Inclusion Criteria:\n\n* Signed Informed Consent Form (ICF)\n* Age ≥ 18 years\n* (Self-)admission to the involved Acute Admissions Unit (AAU)\n* \"Lead symptom\" identified as coughing, back pain or abdominal discomfort\n* Participant within ESI triage system group 4 (standard) and 5 (non-urgent)\n* German-speaking\n* Ownership of a smartphone or other mobile device with iOS or Android operating system\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Participant whose compliance to the study's protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted\n* Participant with insufficient knowledge about the use of a smartphone or other mobile device with iOS or Android operating system\n* Participant already using or planning to use another comparable electronic patient-reported symptom monitoring system (e.g. CANKADO) during this trial",{"count":147,"type":20},417,[23],"The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort.\n\nThe main question it aims to answer is:\n\nCan the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission?\n\nResearchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations.\n\nParticipants will:\n\n* use the medidux™ app to monitor their symptoms and vital parameters for 7 days after discharge (intervention arm).\n* receive follow-up consultations at day 7 and at day 28 to assess symptom progression and any healthcare interactions (both arms).",[151,152,153,154,155,156,157,158,159,27],"Acute Disease","Acute Hospitalization","Coughing","Back Pain","Abdominal Pain (AP)","Patient Discharge","Patient Readmission","Mobile Health Apps","Mobile Health Technology (mHealth)",[151,156,157,153,154,161,162,163,164,165,166,167,168],"Abdominal Pain","Mobile Health Applications","Remote Monitoring","Post-discharge Care","Symptom Monitoring","Health Behaviour","Telemedicine","Randomized Controlled Trial","2025-09-29",{"date":171,"type":42},"2025-10-03",{"date":173,"type":42},"2025-09-28",{"date":175,"type":20},"2027-03-28",{"name":177,"class":49},"Mobile Health AG",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":184,"sex":17,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":188,"conditions":189,"keywords":193,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":50},"100600180","clinical-and-radiographic-outcomes-of-the-jointmedica-custom-made-resurfacing-device-100600180","NCT07094139","Clinical and Radiographic Outcomes of the JointMedica Custom-Made Resurfacing Device","Inclusion Criteria:\n\n* Age 21 or above at the time of the surgery.\n* Have had the JointMedica Custom-Made Hip Resurfacing device implanted between September 2020 to January 2025\n* Written informed consent given by subject\n\nExclusion Criteria:\n\n* There is no exclusion criteria for this study",true,"21 Years",{"count":187,"type":20},41,"The Custom Resurfacing (CR) Implants are indicated for use for the reduction or relief of pain and\u002For improved hip function all skeletally mature patients where a total joint replacement is indicated, and where there is no other suitable, commercially distributed device available.\n\nThe Resurfacing System is a metal-on-polyethylene hip resurfacing device consisting of a metallic femoral component and an acetabular component made of Vitamin E HXLPE with a titanium coating on its bone-contacting surface.\n\nThe custom-Made Hip Resurfacing System is a single use device intended for hybrid fixation: cemented femoral head component and cementless acetabular component.\n\nThe goal of this observational study is to generate Real World Evidence (RWE) on the device performance of the Polymotion Hip Resurfacing (PHR) system and its use in patients who have been implanted with the device for the treatment of hip osteoarthritis.\n\nThis study will assess the following endpoints:\n\n* The survivorship of the Acetabular Cup (Kaplan-Meier estimate) through 2 years of follow-up.\n* Radiographic success of the implanted cups, through quantitative motion analysis to assess migration of the acetabular cups.\n* Absence of subsequent surgical intervention at the acetabulum of there operated hip.\n* Absence of serious, device-related adverse events.\n* Patient reported outcomes through Harris Hip Score and SUSHI - UCLA Hip Score questionnaires.",[190,191,192,27],"Healthy","Real World Data","Safety and Effectiveness",[194,195,196],"Custom-Made Hip Resurfacing","Hip Resurfacing","Hip Arthroplasty","2025-07-23",{"date":199,"type":42},"2025-07-30",{"date":201,"type":20},"2025-08",{"date":203,"type":20},"2026-12",{"name":205,"class":76},"JointMedica Inc.",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":184,"sex":17,"minAge":185,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100599144","clinical-and-radiographic-outcomes-of-the-jointmedica-polymotion-resurfacing-phr-device-100599144","NCT07080671","Clinical and Radiographic Outcomes of the JointMedica Polymotion Resurfacing (PHR) Device","Inclusion Criteria:\n\n* Age 21 or above at the time of the surgery.\n* Have had the Polymotion Hip Resurfacing (PHR) (implanted between September 2020 to January 2025\n* Written informed consent given by subject\n\nExclusion Criteria:\n\n* There is no exclusion criteria for this study",{"count":213,"type":20},105,"The goal of this observational study is to generate Real World Evidence (RWE) on the device performance of the Polymotion Hip Resurfacing (PHR) system and its use in patients who have been implanted with the device for the treatment of hip osteoarthritis.\n\nThis study will assess the following endpoints:\n\n* The survivorship of the Acetabular Cup (Kaplan-Meier estimate) through 2 years of follow-up.\n* Radiographic success of the implanted cups, through quantitative motion analysis to assess migration of the acetabular cups.\n* Absence of subsequent surgical intervention at the acetabulum of there operated hip.\n* Absence of serious, device-related adverse events.\n* Patient reported outcomes through Harris Hip Score and SUSHI - UCLA Hip Score questionnaires.",[190,191,192,27],[217,218,219],"PHR","Polymotion Hip Resurfacing","Polymotion","2025-07-15",{"date":197,"type":42},{"date":223,"type":20},"2025-07-25",{"date":225,"type":20},"2026-12-31",{"name":205,"class":76},3]